We optimize biopharmaceutical R&D productivity, commercial value, and patient outcomes through our scalable end-to-end platform integrating biosimulation, regulatory science, and market access solutions.
Our customers include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries. Since 2014, customers who use Certara’s biosimulation software and technology-enabled services have received over 90% of all new drug and biologic approvals by the FDA.
PRINCETON, N.J. , July 27, 2021 (GLOBE NEWSWIRE) -- Certara (NASDAQ: CERT), a global leader in biosimulation, today announced that Mubadala Investment Company (Mubadala) has made an approximately $250 million investment in Certara . The investment aligns with Mubadala’s strategy of enabling
Certara’s Vaccine Simulator™ Accurately Predicted Optimal Timing Between Doses for COVID-19
Jul 23, 2021
Clinical Study Confirms Quantitative Systems Pharmacology (QSP) Prediction, Showcasing the Power of Biosimulation Technology PRINCETON, N.J. , July 23, 2021 (GLOBE NEWSWIRE) -- Certara , a global leader in biosimulation, today announced that its Vaccine Simulator accurately predicted that eight
PRINCETON, N.J. , July 15, 2021 (GLOBE NEWSWIRE) -- Certara , a global leader in biosimulation, today announced the appointments of Nancy Killefer and Cynthia Collins to its board of directors, effective August 1, 2021 . The two additional appointments increase the company’s board of directors to